Skip to main content
. Author manuscript; available in PMC: 2014 Nov 17.
Published in final edited form as: Mol Cancer Res. 2009 Jan;7(1):41–54. doi: 10.1158/1541-7786.MCR-08-0021

FIGURE 3.

FIGURE 3

Surface plasmon resonance analysis shows that the R251Q mutation abrogates ligand binding. A and B. Increasing concentrations of wild-type (WT; A) or R251Q FGFR2c mutant ectodomain (B) were injected over a CM5 chip onto which full-length human FGF2 was immobilized. The biosensor chip response is plotted as a function of time. Surface plasmon resonance analysis was done as previously described (19).